PharmaCieloPCLOF +27.76% 14-Day RSI is 41.17 as of Jun. 29, 2026. The stock has 5 warning signs investors should review. Among 1,046 Drug Manufacturers companies, PharmaCielo ranks worse than 53.06% on this metric.
The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.
As of today (2026-06-29), PharmaCielo's 14-Day RSI is 41.17.
The industry rank for PharmaCielo's 14-Day RSI or its related term are showing as below:
PCLOF's 14-Day RSI is ranked worse than 53.06% of 1046
companies
in the Drug Manufacturers industry
Industry Median: 43.745
vs PCLOF: 41.17
PharmaCielo (OTCPK:PCLOF) 14-Day RSI Explanation
The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.
Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.
RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.
PharmaCielo 14-Day RSI Related Terms
PCLOF vs ZTS, UTHR: 14-Day RSI Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaCielo's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaCielo 14-Day RSI vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaCielo's 14-Day RSI distribution charts can be found below:
* The bar in red indicates where PharmaCielo's 14-Day RSI falls into.
* Note that the formula uses a positive value for the average loss.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PharmaCielo (PCLOF) has a 14-Day RSI of 41.17 as of Jun. 29, 2026. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PharmaCielo and its competitors. According to the industry distribution chart, PharmaCielo ranks #555 out of 1046 companies in the Drug Manufacturers industry, placing it in the top 53.1%.
Is PharmaCielo's 14-Day RSI too high?
PharmaCielo's current 14-Day RSI is 41.17. The Drug Manufacturers industry median 14-Day RSI is 43.75. PharmaCielo's value of 41.17 is 5.9% below this industry median. Based on the distribution chart, PharmaCielo ranks #555 out of 1046 companies in the Drug Manufacturers industry, which is below the industry midpoint.
How does PharmaCielo's 14-Day RSI compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaCielo ranks #555 out of 1046 companies for 14-Day RSI. This places PharmaCielo in the lower half of its industry. The industry median 14-Day RSI is 43.75. PharmaCielo's value of 41.17 is 5.9% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 14-Day RSI for a Drug Manufacturers company?
The median 14-Day RSI among Drug Manufacturers companies is 43.75, based on 1,046 companies in the industry. Companies in the top quartile (top 25%) have a 14-Day RSI significantly above this median, while those in the bottom quartile fall well below. However, 14-Day RSI should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaCielo's current 14-Day RSI of 41.17 is 5.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 14-Day RSI mean?
A high 14-Day RSI can signal that a stock is expensive relative to its fundamentals. Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. View historical data on PharmaCielo and its competitors. For the Drug Manufacturers industry, the median 14-Day RSI is 43.75 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaCielo's current 14-Day RSI is 41.17. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaCielo stock overvalued right now?
Based on GuruFocus' analysis, PharmaCielo (PCLOF) is currently considered Possible Value Trap. The stock's GF Value™ is $0.11, compared to a current price of $0.06 — trading 44.3% below its estimated fair value. The current 14-Day RSI is 41.17 and 5.9% below the Drug Manufacturers industry median of 43.75. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 14-Day RSI calculated?
14-Day RSI is calculated from a company's financial statements. For PharmaCielo (PCLOF), the current 14-Day RSI is 41.17 as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
PharmaCielo Ltd is a pharma company, with a focus on ethical and sustainable processing and supplying of both THC(tetrahydrocannabinol) and CBD (cannabidiol) medicinal cannabis extracts. It is licensed to produce both CBD-dominant and THC-dominant cannabis extracts. The company operates in Canada, Colombia, Italy, and Mexico and generates the majority of its revenue in the form of the Sale of Cannabis derivative products in America followed by Australia, Africa and Europe.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
PCLOF has been successfully added to your